Infliximab therapy together with tyrosine kinase inhibition targets leukemic stem cells in chronic myeloid leukemia

BACKGROUND: Expression of Bcr-Abl in hematopoietic stem cells is sufficient to cause chronic myeloid leukemia (CML) and tyrosine kinase inhibitors (TKI) induce molecular remission in the majority of CML patients. However, the disease driving stem cell population is not fully targeted by TKI therapy,...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:BMC Cancer
Autori principali: Herrmann, Oliver, Kuepper, Maja Kim, Bütow, Marlena, Costa, Ivan G., Appelmann, Iris, Beier, Fabian, Luedde, Tom, Braunschweig, Till, Koschmieder, Steffen, Brümmendorf, Tim H., Schemionek, Mirle
Natura: Artigo
Lingua:Inglês
Pubblicazione: BioMed Central 2019
Soggetti:
Research Article
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC6610865/
https://ncbi.nlm.nih.gov/pubmed/31272418
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12885-019-5871-2
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi